Cailin Conner

DocwireNews

Investigators conducted cost-effectiveness analyses of allotransplantation therapy for pediatric patients with sickle cell disease (SCD) in the United States and found that this treatment is an &ldquo;equitable&rdquo; option. The results were presented at the 65th ASH Annual Meeting &amp; Exposition.&ldquo;Prior research has shown that even if gene therapy is conventionally cost-ineffective versus the standard of care (SOC), it can be a justifiable treatment option for a historically marginalized patient population in the United States, as demonstrated by equity-weighted cost-effectiveness,&rdquo; the investigators wrote. &ldquo;For allotransplantation and gene therapy, neither conventional nor distributional (ie, equity-weighted) cost-effectiveness is known.&rdquo;Therefore, the researchers constructed a Markov model to assess the cost-effectiveness of allotransplantation, gene therapy, and SOC for pediatric patients with SCD. Data from 11 years of US commercially insured patients informed the analysis. The SOC included various treatments, and costs for allotransplantation and graft-versus-host disease were based on prior literature. Quality-adjusted life-years (QALYs) were determined using lifetime simulations. Conventional cost-effectiveness was assessed with an incremental cost-effectiveness ratio (ICER).The study also conducted a distributional cost-effectiveness analysis to address health inequities, comparing results to commonly used equity weights in the United States (range, 0.5-3.0). The maximum starting age for allotransplantation was set at 12 years, and gene therapy was assumed to cost $2.45 million with 100% effectiveness.Regarding the results of their analyses, the investigators state, &ldquo;Allotransplantation also appears to be an equitable therapeutic option for pediatric patients with sickle cell disease, regardless of conventional cost-ineffectiveness and as compared to SOC.&rdquo;Costs associated with each therapy were:<ul>
<li>$1.9 million for allotransplantation</li>
<li>$2.8 million for gene therapy</li>
<li>$1.0 million for SOC</li>
</ul>Discounted lifetime QALY for each option was:<ul>
<li>1 for allotransplantation</li>
<li>5 for gene therapy</li>
<li>7 for SOC</li>
</ul>The ICERs and equity weight thresholds for allotransplantation (compared with SOC) were $138,000/QALY and 0.5, while for gene therapy (compared with allotransplantation), they were $253,000/QALY and 4.5, respectively.&ldquo;The consideration of patient-population-specific equity offers an important opportunity to derive transparent benchmarks for intertwined equity- and value-informed decision making. Quantitative consideration of equity in the context of conventional cost-ineffectiveness can be an important tipping point in justification of funding,&rdquo; the researchers concluded.ReferenceGoshua G, Ito S, Chetlapalli K, et al. Allotransplantation and gene therapy equity for children with sickle cell disease: distributional cost-effectiveness of allotransplantation vs gene therapy vs standard-of-care in pediatric patients with sickle cell disease in the United States. Abstract #490. Presented at the 65th American Society of Hematology Annual Meeting; December 9-12, 2023; San Diego, California.

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Hatem Soliman, MD

Using Dendritic Cell Vaccines to Boost Neoadjuvant Therapy in HER2+ Breast Cancer

HER2 Breast Cancer

Kathleen Liu, MD

Joel M. Topf, MD, FACP

AKI Approaches and ASN Kidney Health Guidance

NKF Spring Clinical Meetings 2025

Latest News

Cost-Effective Analysis Identifies Allotransplantation as an Equitable Therapy for Pediatric Patients with SCD

Sickle Cell Disease

Allotransplantation had "equitable" cost-efficacy in pediatric patients with sickle cell disease in the United States.

Cost-Effective Analysis Identifies Allotransplantation as an Equitable Therapy for Pediatric Patient

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe